Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs BIO-TECHNE Corp (TECH) Price & Performance

MSTU is experiencing significant downward pressure with the stock declining 13.68% to $39.45 amid bearish technical signals. The reverse stock split effective August 24, 2026, and upcoming dividend payment suggest corporate restructuring efforts. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support levels cluster around $36-38.

The outlook remains challenging with technical weakness and limited fundamental visibility. Investment opportunity exists for contrarian investors betting on stabilization, though risks include continued volatility from leveraged ETF mechanics and dependence on underlying stock performance. The absence of key financial ratios warrants caution for fundamental investors.

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.